Key Takeaways
- Liquidia (NASDAQ:LQDA) rose 30.62% to USD 35.02 in the October 14, 2026 morning session, following an opening gap of 33.16% and volume of 7.585 million shares. The move followed the global settlement with United Therapeutics announced on October 13, 2026.
- The settlement calls for total net payments of USD 380.7 million: USD 175 million to United Therapeutics, two installments totalling USD 145.4 million at USD 72.7 million each, and USD 60.3 million to other parties.
- Liquidia’s preliminary and unaudited third-quarter net product sales for Yutrepia were USD 222.7 million. Cash and cash equivalents stood at USD 396.1 million on September 30, 2026, according to the company’s release.
- A Delaware court ruled on September 30, 2026 that claims 1 and 14 of U.S. Patent No. 11,826,327 were valid and infringed. Liquidia shares dropped 57.19% to USD 30.26 that day.
The Agreement Removes One Major Legal Uncertainty
In its October 13, 2026 announcement, Liquidia said it would not appeal the September 30 decision and had submitted a label supplement removing the pulmonary-hypertension-associated-with-interstitial-lung-disease indication from Yutrepia. The agreement settles six lawsuits, with dismissals with prejudice following the initial payment. Yutrepia will remain available without interruption for patients with pulmonary arterial hypertension (PAH). Liquidia also terminated its promotional agreement for Treprostinil Injection. The settlement reduces the risk of an open-ended injunction while the court’s remedy had remained undecided. The underlying patent concerned inhaled treprostinil for the disputed indication, and Liquidia had admitted infringement, leaving remedy and damages as the central contested issues.
The Payment Calendar Will Put Pressure on Liquidity
Liquidia must make the USD 175 million initial payment within 30 business days, followed by installments due January 31, 2027 and April 30, 2027. The USD 396.1 million cash balance is close to the USD 380.7 million total net obligation, so maintaining liquidity will depend in part on Yutrepia sales. Management said payments would be funded from revenue and cash on hand. CFO Michael Kaseta said the company expects to finance its planned clinical studies without additional funding. The company continues post-marketing work and pivotal studies of L606 for PAH and interstitial lung disease. Treprostinil is a prostacyclin analogue, and Yutrepia is an inhaled dry-powder formulation; the narrower label therefore determines which patients can be targeted and the uses for which the product can be promoted.
Commercial Scope and Cash Use Are the Next Tests
Removing the interstitial lung disease indication from the label limits Yutrepia’s addressable commercial scope and is a key business risk. The settlement payments are substantial relative to cash, while management’s funding plan assumes continued sales performance. Investors should track the first payment, legal dismissal filings and the third-quarter earnings call planned for November; the precise date was not available at publication. The sales figures are preliminary and unaudited and may change. While the settlement ends additional litigation and uncertainty around damages, the scheduled payments extend through April 2027 and reduce funds available for research. A slowdown in sales after the label change remains possible. This article is not investment advice.
How the Settlement Changes the Picture
Liquidia (NASDAQ:LQDA) advanced 30.62% after its October 13, 2026 agreement with United Therapeutics reduced the risk of further litigation over Yutrepia, which will continue to be sold for PAH. The trade-off is a net payment obligation of USD 380.7 million against USD 396.1 million in cash at September 30. The planned November third-quarter earnings call is the next scheduled milestone, although a specific date had not been announced. This is not investment advice.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...